Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dorien Pastoors

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
International Journal of Cancer|January 24, 2025
Mechanisms of enhancer-driven oncogene activationJoyce Vriend, Ruud Delwel, Dorien Pastoors
Science Advances|May 15, 2024
Oncogene <i>EVI1</i> drives acute myeloid leukemia via a targetable interaction with CTBP2Dorien Pastoors, Marije Havermans, Roger Mulet-Lazaro, et al.
Blood|October 8, 2025
MECOM is a master repressor of myeloid differentiation through dose control of CEBPA in acute myeloid leukemiaDorien Pastoors, Marije Havermans, Roger Mulet-Lazaro, et al.
Cancer Discovery|May 13, 2021
Selective Requirement of MYB for Oncogenic Hyperactivation of a Translocated Enhancer in LeukemiaLeonie Smeenk, Sophie Ottema, Roger Mulet-Lazaro, et al.
Cancer Cell|December 16, 2022
IL-5-producing CD4<sup>+</sup> T cells and eosinophils cooperate to enhance response to immune checkpoint blockade in breast cancerOlga S Blomberg, Lorenzo Spagnuolo, Hannah Garner, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
International Journal of Cancer|January 24, 2025
Mechanisms of enhancer-driven oncogene activationJoyce Vriend, Ruud Delwel, Dorien Pastoors
Science Advances|May 15, 2024
Oncogene <i>EVI1</i> drives acute myeloid leukemia via a targetable interaction with CTBP2Dorien Pastoors, Marije Havermans, Roger Mulet-Lazaro, et al.
Blood|October 8, 2025
MECOM is a master repressor of myeloid differentiation through dose control of CEBPA in acute myeloid leukemiaDorien Pastoors, Marije Havermans, Roger Mulet-Lazaro, et al.
Cancer Discovery|May 13, 2021
Selective Requirement of MYB for Oncogenic Hyperactivation of a Translocated Enhancer in LeukemiaLeonie Smeenk, Sophie Ottema, Roger Mulet-Lazaro, et al.
Cancer Cell|December 16, 2022
IL-5-producing CD4<sup>+</sup> T cells and eosinophils cooperate to enhance response to immune checkpoint blockade in breast cancerOlga S Blomberg, Lorenzo Spagnuolo, Hannah Garner, et al.
Pageof 1